Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 15/20 | 0.65 |
| ▸ | HDAC3 | O15379 | 13/20 | 0.65 |
| ▸ | HDAC6 | Q9UBN7 | 12/20 | 0.65 |
| ▸ | HDAC8 | Q9BY41 | 11/20 | 0.65 |
| ▸ | HDAC5 | Q9UQL6 | 7/20 | 0.65 |
| ▸ | HDAC4 | P56524 | 6/20 | 0.65 |
| ▸ | HDAC2 | Q92769 | 10/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | HDAC10 | Q969S8 | 5/20 | 0.49 |
| ▸ | HDAC7 | Q8WUI4 | 4/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.48 |
| ▸ | HDAC9 | Q9UKV0 | 4/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17483891 | 0.88 | HDAC1 (0.71) | HDAC1HDAC3HDAC6HDAC8HDAC5 | |
| SCHEMBL13949789 | 0.80 | HDAC1 (0.75) | HDAC1HDAC3HDAC6HDAC8HDAC5 | |
| SCHEMBL17483888 | 0.79 | HDAC1 (1.00) | HDAC1HDAC3HDAC6HDAC8HDAC5 | |
| SCHEMBL4925029 | 0.79 | HDAC1 (0.61) | HDAC1HDAC3HDAC6HDAC8HDAC5 | |
| SCHEMBL4925021 | 0.79 | HDAC1 (0.61) | HDAC1HDAC3HDAC6HDAC8HDAC5 | |
| SCHEMBL12049804 | 0.77 | NR1D1 (0.48) | HDAC1HDAC6 | |
| SCHEMBL14340366 | 0.76 | HDAC1 (0.44) | HDAC1HDAC3HDAC6HDAC8HDAC5 | |
| SCHEMBL18088414 | 0.74 | HDAC1 (1.00) | HDAC1HDAC3HDAC6HDAC8HDAC5 | |
| SCHEMBL13949857 | 0.73 | HDAC1 (0.79) | HDAC1HDAC3HDAC6HDAC8HDAC5 | |
| SCHEMBL12150981 | 0.73 | HDAC6 (1.00) | HDAC1HDAC3HDAC6HDAC8HDAC5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210060014-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | CERENO SCIENTIFIC AB (SE) | 2021-03-04 | — | — | US | disclosed |
| US-20170020874-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | CERENO SCIENT AB (SE) | 2017-01-26 | — | — | US | disclosed |
| US-20140051716-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | CERENO SCIENTIFIC AB | 2014-02-20 | — | — | US | disclosed |
| US-20140051716-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | CERENO SCIENTIFIC AB | 2014-02-20 | — | — | US | disclosed |
| US-20090012066-A1 | Method of Use of Deacetylase Inhibitors | NOVARTIS AG | 2009-01-08 | — | — | US | disclosed |
| US-20090012066-A1 | Method of Use of Deacetylase Inhibitors | NOVARTIS AG | 2009-01-08 | — | — | US | disclosed |
| US-20080176849-A1 | DEACETYLASE INHIBITORS | SECURA BIO, INC. | 2008-07-24 | — | — | US | disclosed |
| US-20080176849-A1 | DEACETYLASE INHIBITORS | SECURA BIO, INC. | 2008-07-24 | — | — | US | disclosed |
| WO-2007021682-A1 | METHOD OF USE OF DEACETYLASE INHIBITORS | NOVARTIS AG (CH) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051716-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | HDAC3, HDAC1, HDAC2 | HDAC1 2/4885HDAC3 1/4885HDAC6 10/4885 |
| US-20170020874-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | HDAC3, HDAC1, HDAC2 | HDAC1 2/4885HDAC3 1/4885HDAC6 10/4885 |
| US-20080176849-A1 | DEACETYLASE INHIBITORS | HDAC1, HDAC3, HDAC6 | HDAC1 1/4885HDAC3 2/4885HDAC6 3/4885 |
| US-20090012066-A1 | Method of Use of Deacetylase Inhibitors | HDAC3, HDAC5, HDAC1 | HDAC1 3/4885HDAC3 1/4885HDAC6 10/4885 |
| US-20210060014-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | HDAC3, HDAC1, HDAC2 | HDAC1 2/4885HDAC3 1/4885HDAC6 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.